The company seeks to accelerate drug development by automating analysis of study samples.

The transaction is expected to close on or about July 28, 2025, subject to satisfaction of customary closing conditions. The Company intends to use the net proceeds from the offering to fund ...

Kristin Cabot, Astronomer's HR chief, faces backlash after a viral kiss cam video and contradicted her public claims of ...

Boster Bio pioneers free antibody validation, revolutionizing IHC services with guaranteed reagent reliability, setting new ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com ...

Dash's Fully Automated Bioanalysis Platform Is Reshaping Drug Development with Speed, Precision, and Scale. NEWTON, Mass., ...

While it seems like every industry will be affected in some way by agents, for the first time, the scale of a business is not ...

VISTA, an AI-controlled data loop system, guides large-scale antibody design from scratch for applications in cancer therapy.

Senti Bio’s Chief Medical Officer, Kanya Rajangam, M.D., Ph.D. to Give Feature Presentation at the BioScience Forum ...